Derms on Drugs

Patch Me If You Can

Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hidi

The Clot Thickens

Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clo

The Long and Short of Male Genital Disease

Male genital disease expert Dr. Christopher Bunker joins the Derms for the penis episode no one else was brave enough to make. Lichen sclerosus, circumcision, penile canc

Three Sheets to Tofa

The Derms debut a shorter format with three papers and one newly dirt-cheap drug: generic tofacitinib. The safety, the risks, and the practicalities—right down to getting

Creams, Screams, and Measles

Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections

Can We Stop Referring CSU?

The CSU rulebook is getting a rewrite, and the Derms on Drugs crew has thoughts. Dr. Jason Hawkes joins the conversation to talk new guidelines, new therapies, and why it

The Gray Zone Strikes Again

This week, the DoD tackle studies that leave plenty of room for debate—from skin cancer treatment costs and melanoma risk to HS, alopecia areata, and the real-world decis

Making Nails Sexy Again

The DOD tackle longitudinal melanonychia, retronychia, nail biopsies, and other everyday nail problems—with enough practical pearls to make you rethink your next nail pat

Clinical Controversies: Screening, Patch Testing & Physician Burnout

One paper questions melanoma screening. Another challenges patch testing. By the end, the conversation has wandered into studies on physician burnout and more, sparking e

What If the Biopsy Picked the Biologic?

Dermatologist William Damsky, MD, joins the DoD crew to explore immune biomarkers, treatment prediction, and whether precision dermatology is finally ready for prime time

Don't Blame the Canary

Burnout isn't just about long hours. From moral distress to prior authorizations and system barriers, this week's conversation with Dr. Lisa Swanson explores what's reall

Bad Ideas, Good Outcomes, and Thin Melanomas

Thin melanomas that behave badly, a surprisingly intriguing role for oxybutynin in HS, and a reminder that some of dermatology’s most trusted assumptions deserve a second

When Psoriasis Pretends to Be Eczema (And Other Problems)

The diagnoses get messy, the treatment decisions get interesting, and the DoD crew has opinions. From a major scabies study to a practical overlap-disease pearl, this wee

French Bathhouses, Vitiligo Hacks & the Myth of the ‘Cure’

An emerging infection out of France, a surprisingly clever vitiligo combo, and a spirited debate about whether medicine has ever actually cured anything. Just another nor

Rewind: Melanoma Meltdowns, Biosimilar Betrayals, and the Eczema Enigma Exposed!

Melanoma, Anxiety, and Depression Links; Biosimilars vs Humira; Air Pollution and Atopic Dermatitis – Have We Finally Figured Out Why Eczema Is So Common and much, much m

PsA: The Derm Version

Psoriatic arthritis usually gets explained in a way that makes derms want to leave the room. Not this episode. Drs. Zirwas, Ferris, and Patton are joined by double-boarde

Sunscreen Heresy & Other Hot Takes

This week’s Derms on Drugs is a classic six-pack episode. From cutting-edge CTCL therapies to biologic safety data and the growing world of oral photoprotection, the grou

Steroids, Estrogen & Other Bad Decisions

This week on Derms on Drugs, the gang goes deep into vulvar dermatology with double-boarded derm/OB-GYN expert Dr. Kelly Tyler. From lichen sclerosus and recurrent candid

Pick Your Own Treatment Adventure

This week’s Derms on Drugs is a 6-pack that covers a little bit of everything and somehow lands on: just do what you want. From a randomized trial showing eczema doesn’t

Regenerative Derm: Baloney or Breakthrough?

Feeling a little worn down by Friday? A bit… degenerated, perhaps? This week’s Derms on Drugs goes off the beaten path and into the world of regenerative dermatology, whe